Filing Flows › Companies › Edwards Lifesciences › Report card
Edwards Lifesciences earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate4 of 5 reports beat the EPS estimate
Edwards Lifesciences (EW) beat the analysts' EPS estimate in 4 of its last 5 reports (80%), by +5.5% on average. On report days the stock moved 3.2% in either direction on median (largest 5.9%), rising 60% of the time; after a beat it rose 50% of the time.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue guided | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | Nov 4, 2026 | $0.74 | $0.80 | +8.6% | $1.6B–$1.7B | $1.7B (above) | +5.9% | +8.7% |
| Q2 2026 | Jul 23, 2026 | $0.74 | $0.78 | +5.3% | $1.7B–$1.7B | $1.7B (within) | -2.1% | -0.9% |
| Q1 2026 | Apr 23, 2026 | $0.73 | $0.78 | +7.3% | $1.6B–$1.6B | $1.6B (above) | +3.2% | +2.8% |
| Q4 2025 | Feb 10, 2026 | $0.62 | $0.58 | -6.3% | $1.5B–$1.6B | $1.6B (within) | +3.3% | +3.6% |
| Q3 2025 | Oct 30, 2025 | $0.59 | $0.67 | +12.6% | $1.5B–$1.5B | $1.6B (above) | -0.3% | +0.5% |
Estimates and reported EPS are the Street's adjusted figures. Revenue guided is the last range the company gave before the report. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 5 reports the stock moved 3.2% on median on the day (close to close), the largest move 5.9%.
After a beat the stock rose 50% of the time (4 beats).
How credible is its guidance?
Revenue: of 9 guided periods, 5 came in beyond the top end of the range, 3 within and 1 short of it; 8 of 9 on the better side of the midpoint, on average +0.4% against the midpoint (+ is better). Guidance has been conservative: results land in the better half. On that record the odds the next lands on the better side of the midpoint are about 82%.
Position in the range: 0 is the worse end, 1 the better end (for costs and tax rates, lower). Odds are the record plus one each way (Laplace), not a forecast.
The next report: what to expect → Edwards Lifesciences: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.